Drug-Eluting Balloons

This channel includes news and new technology innovations for drug-coated balloons (DCB), also referred to as drug-eluting balloons. These are used to treat peripheral and coronary artery lesions and restenosis. The balloons carry an antiproliferative drug that is delivered to the wall of arteries when the balloon is expanded. The drug helps prevent neointimal hyperplasia (scar tissue growth) caused by trauma when the vessel segment is treated for atherosclerotic lesions with balloon angioplasty. DCBs can be used to treat hyperplasia in arteriovenous (AV) access fistulae in dialysis patients, where the vessel undergoes repeated trauma from regular punctures. DCBs also are used to treat in-stent restenosis due to scar tissue proliferation inside stents, which can cause a vessel to occlude.

News | Drug-Eluting Balloons

September 20, 2019 — Orchestra BioMed Inc., in partnership with Terumo Corp. announced the company has secured ...

Home September 20, 2019
Home
News | Peripheral Artery Disease (PAD)

August 27, 2019 — Concept Medical was recently granted Breakthrough Therapy designation by the U.S. Food and Drug ...

Home August 27, 2019
Home
News | Peripheral Artery Disease (PAD)

August 14, 2019 — Concept Medical Inc. (CMI) has been granted "Breakthrough Device Designation" from the U.S. Food and ...

Home August 14, 2019
Home
News | Drug-Eluting Balloons

August 2, 2019 — B. Braun Interventional Systems Inc. (BIS) announced the U.S. Food and Drug Administration (FDA) has ...

Home August 02, 2019
Home
News | Drug-Eluting Balloons

June 13, 2019 — Orchestra BioMed Inc. announced it has formed a global strategic partnership with Terumo Corp. for ...

Home June 13, 2019
Home
News | Drug-Eluting Balloons

May 29, 2019 — Philips announced the three-year results from the ILLUMENATE Pivotal trial and the ILLUMENATE European ...

Home May 29, 2019
Home
News | Drug-Eluting Balloons

May 2, 2019 — Concept Medical Inc. (CMI) has been granted Breakthrough Device Designation from the U.S. Food and Drug ...

Home May 02, 2019
Home
Technology | Drug-Eluting Balloons

April 24, 2019 —  Orchestra BioMed Inc. has secured Breakthrough Device designation by the U.S. Food and Drug ...

Home April 24, 2019
Home
News | Drug-Eluting Balloons

March 6, 2019 – Swiss-based M.A. MedAlliance SA has been granted Breakthrough Device Designation from the U.S. Food and ...

Home March 06, 2019
Home
News | Drug-Eluting Balloons

January 28, 2019 — Philips announced the latest pooled analysis of patient-level data of over 2,300 patients treated ...

Home January 28, 2019
Home
News | Peripheral Artery Disease (PAD)

January 17, 2019 — The U.S. Food and Drug Administration (FDA) issued a letter Jan. 17, 2019, to healthcare providers ...

Home January 17, 2019
Home
News | Drug-Eluting Balloons

September 25, 2018 — Orchestra BioMed Inc. announced the three-year clinical results from its Sirolimus Angioplasty ...

Home September 25, 2018
Home
News | Drug-Eluting Balloons

September 24, 2018 — New data announced at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21 ...

Home September 24, 2018
Home
Technology | Drug-Eluting Balloons

June 15, 2018 — Medtronic plc has received U.S. Food and Drug Administration (FDA) approval for 200mm and 250mm lengths ...

Home June 15, 2018
Home
News | Drug-Eluting Balloons

May 29, 2018 – M.A. MedAlliance SA has raised $37 million to help develop and commercialize the first sirolimus micro ...

Home May 29, 2018
Home
Subscribe Now